Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher B Cooper

Showing results (121-130 of 253) with videos related to

Pageof 26
Sort By:
European Journal of Medicinal Chemistry|December 28, 2021
Synthesis and structure-activity relationships for a new class of tetrahydronaphthalene amide inhibitors of Mycobacterium tuberculosisHamish S Sutherland, Guo-Liang Lu, Amy S T Tong, et al.
Molecules (Basel, Switzerland)|May 28, 2020
Synergistic Activity of Nitroimidazole-Oxazolidinone Conjugates against Anaerobic BacteriaZhijun Zhuang, Dawei Wan, Jun Ding, et al.
Bioorganic & Medicinal Chemistry|October 2, 2020
Synthesis and structure-activity relationships for tetrahydroisoquinoline-based inhibitors of Mycobacterium tuberculosisGuo-Liang Lu, Amy S T Tong, Daniel Conole, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|August 7, 2025
Diagnosing Type 2 Inflammation in COPD: Comparison of Blood and Sputum Eosinophil Assessment in the University of California Los Angeles COPD Phenotyping StudyW Blake LeMaster, Sarah A Ingersoll, Hyewon Phee, et al.
European Journal of Medicinal Chemistry|December 3, 2020
Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisalAndrew M Thompson, Patrick D O'Connor, Andrew J Marshall, et al.
Medical Physics|May 6, 2016
A controlled statistical study to assess measurement variability as a function of test object position and configuration for automated surveillance in a multicenter longitudinal COPD study (SPIROMICS)Junfeng Guo, Chao Wang, Kung-Sik Chan, et al.
Journal of Medicinal Chemistry|February 21, 2018
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral LeishmaniasisAndrew M Thompson, Patrick D O'Connor, Andrew J Marshall, et al.
Journal of Medicinal Chemistry|May 2, 2017
7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral LeishmaniasisAndrew M Thompson, Patrick D O'Connor, Andrew J Marshall, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|May 12, 2017
Obstructive pulmonary disease in patients with previous tuberculosis: Pathophysiology of a community-based cohortBrian W Allwood, Rencia Gillespie, Maya Galperin-Aizenberg, et al.
Journal of the Academy of Consultation-Liaison Psychiatry|August 10, 2022
Association Among Chronic Obstructive Pulmonary Disease Severity, Exacerbation Risk, and Anxiety and Depression Symptoms in the SPIROMICS CohortJacob R Weiss, Ryan Serdenes, Uchechukwu Madtha, et al.
Pageof 26

Showing results (121-130 of 253) with videos related to

Sort By:
Pageof 26
European Journal of Medicinal Chemistry|December 28, 2021
Synthesis and structure-activity relationships for a new class of tetrahydronaphthalene amide inhibitors of Mycobacterium tuberculosisHamish S Sutherland, Guo-Liang Lu, Amy S T Tong, et al.
Molecules (Basel, Switzerland)|May 28, 2020
Synergistic Activity of Nitroimidazole-Oxazolidinone Conjugates against Anaerobic BacteriaZhijun Zhuang, Dawei Wan, Jun Ding, et al.
Bioorganic & Medicinal Chemistry|October 2, 2020
Synthesis and structure-activity relationships for tetrahydroisoquinoline-based inhibitors of Mycobacterium tuberculosisGuo-Liang Lu, Amy S T Tong, Daniel Conole, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|August 7, 2025
Diagnosing Type 2 Inflammation in COPD: Comparison of Blood and Sputum Eosinophil Assessment in the University of California Los Angeles COPD Phenotyping StudyW Blake LeMaster, Sarah A Ingersoll, Hyewon Phee, et al.
European Journal of Medicinal Chemistry|December 3, 2020
Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisalAndrew M Thompson, Patrick D O'Connor, Andrew J Marshall, et al.
Medical Physics|May 6, 2016
A controlled statistical study to assess measurement variability as a function of test object position and configuration for automated surveillance in a multicenter longitudinal COPD study (SPIROMICS)Junfeng Guo, Chao Wang, Kung-Sik Chan, et al.
Journal of Medicinal Chemistry|February 21, 2018
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral LeishmaniasisAndrew M Thompson, Patrick D O'Connor, Andrew J Marshall, et al.
Journal of Medicinal Chemistry|May 2, 2017
7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral LeishmaniasisAndrew M Thompson, Patrick D O'Connor, Andrew J Marshall, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|May 12, 2017
Obstructive pulmonary disease in patients with previous tuberculosis: Pathophysiology of a community-based cohortBrian W Allwood, Rencia Gillespie, Maya Galperin-Aizenberg, et al.
Journal of the Academy of Consultation-Liaison Psychiatry|August 10, 2022
Association Among Chronic Obstructive Pulmonary Disease Severity, Exacerbation Risk, and Anxiety and Depression Symptoms in the SPIROMICS CohortJacob R Weiss, Ryan Serdenes, Uchechukwu Madtha, et al.
Pageof 26